Author:
del Puerto-Nevado L,Rojo F,Zazo S,Caramés C,Rubio G,Vega R,Chamizo C,Casado V,Martínez-Useros J,Rincón R,Rodríguez-Remírez M,Borrero-Palacios A,Cristóbal I,Madoz-Gúrpide J,Aguilera O,García-Foncillas J
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Castellano D, Ravaud A, Schmidinger M, De Velasco G, Vazquez F (2013) Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers. Cancer Treat Rev 39: 230–240.
2. Connolly DT (1991) Vascular permeability factor: a unique regulator of blood vessel function. J Cell Biochem 47: 219–223.
3. Chaudhary R, Bromley M, Clarke NW, Betts CD, Barnard RJ, Ryder WD, Kumar S (1999) Prognostic relevance of micro-vessel density in cancer of the urinary bladder. Anticancer Res 19: 3479–3484.
4. Farace F, Gross-Goupil M, Tournay E, Taylor M, Vimond N, Jacques N, Billiot F, Mauguen A, Hill C, Escudier B (2011) Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br J Cancer 104: 1144–1150.
5. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765–781.